Savant Capital, LLC Fate Therapeutics Inc Transaction History
Savant Capital, LLC
- $17.8 Billion
- Q3 2025
A detailed history of Savant Capital, LLC transactions in Fate Therapeutics Inc stock. As of the latest transaction made, Savant Capital, LLC holds 35,968 shares of FATE stock, worth $34,529. This represents 0.0% of its overall portfolio holdings.
Number of Shares
35,968
Previous 24,205
48.6%
Holding current value
$34,529
Previous $27,000
66.67%
% of portfolio
0.0%
Previous 0.0%
Shares
2 transactions
Others Institutions Holding FATE
# of Institutions
155Shares Held
81.5MCall Options Held
46.4KPut Options Held
17.5K-
Redmile Group, LLC San Francisco, CA12.9MShares$12.4 Million1.79% of portfolio
-
Black Rock Inc. New York, NY10.1MShares$9.71 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA8.8MShares$8.45 Million0.0% of portfolio
-
Wilshire Advisors LLC Santa Monica, CA8.49MShares$8.15 Million27.71% of portfolio
-
Johnson & Johnson New Brunswick, NJ3.38MShares$3.24 Million1.0% of portfolio
About FATE THERAPEUTICS INC
- Ticker FATE
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 97,000,304
- Market Cap $93.1M
- Description
- Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. Its NK- and T-cell immuno-oncology programs under development include FT516 for the treatment of acute myeloid leukemia (AML) B-cell lymphoma, and advanced solid tumor; FT596 to treat B-cell...